References
- Souli M, Karaiskos I, Galani L, et al. Nationwide surveillance of resistance rates of Staphylococcus aureus clinical isolates from Greek hospitals, 2012–2013. Infect Dis (London). 2016;48:287–292.
- Castanheira M, Watters AA, Mendes RE, et al. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). J Antimicrob Chemother. 2010;65:1353–1358.
- Clinical and Laboratory Standards Institute. M100-S27. Performance standards for antimicrobial susceptibility testing: 27th informational supplement. Wayne (PA): CLSI; 2017.
- The European Committee on Antimicrobial Susceptibility Testing. Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST [Internet]. Version 6.0, 2016. Available from: http://www.eucast.org.
- Abd El‐Hamid MI, Bendary MM, Merwad AMA, et al. What is behind phylogenetic analysis of hospital‐, community‐ and livestock‐associated methicillin‐resistant Staphylococcus aureus? Transbound Emerg Dis. 2019;66:1506–1517.
- Elazhari M, Abu-Quatouseh LF, Elhabchi D, et al. Characterization of fusidic acid-resistant Staphylococcus aureus isolates in the community of Casablanca (Morocco). Int J Med Microbiol. 2012;302:96–100.
- Castanheira M, Watters AA, Bell JM, et al. Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007–2008. Antimicrob Agents Chemother. 2010;54:3614–3617.
- Jung MY, Chung JY, Lee HY, et al. Antibiotic susceptibility of Staphylococcus aureus in atopic dermatitis: current prevalence of methicillin-resistant Staphylococcus aureus in Korea and treatment strategies. Ann Dermatol. 2015;27:398–403.